Does Tirzepatide Burn Fat or Just Suppress Appetite? The Dual-Mechanism Answer

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide activates both GLP-1 receptors (appetite suppression) and GIP receptors (fat metabolism), making it a dual-action medication rather than appetite-only
• The GIP component increases lipolysis (fat breakdown) and reduces lipogenesis (fat storage) independent of calorie reduction
• Clinical trials show tirzepatide produces 5-8% greater fat mass loss than semaglutide at equivalent weight loss, suggesting direct metabolic effects beyond appetite
• Most patients experience appetite suppression within 48-72 hours, while metabolic fat-burning effects accumulate over 8-12 weeks

Direct answer (40-60 words)

Tirzepatide does both. It suppresses appetite through GLP-1 receptor activation in the brain and directly promotes fat burning through GIP receptor activation in adipose tissue. The GIP component increases lipolysis and improves fat oxidation independent of reduced calorie intake, distinguishing tirzepatide from single-agonist GLP-1 medications like semaglutide.

Table of contents

1. The mechanism breakdown: GLP-1 vs GIP pathways
2. What the SURMOUNT trials reveal about body composition
3. The fat-burning timeline: when each mechanism activates
4. Why most articles get the GIP receptor story wrong
5. Tirzepatide vs semaglutide: the fat mass comparison
6. The FormBlends dual-phase response pattern
7. When appetite suppression fails but fat loss continues
8. The metabolic advantage framework
9. Real patient scenarios: which mechanism dominates
10. The case against tirzepatide as a fat burner
11. How to tell which mechanism is working for you
12. FAQ

The mechanism breakdown: GLP-1 vs GIP pathways

Tirzepatide is a dual GIP/GLP-1 receptor agonist. This means it activates two separate hormone pathways simultaneously, each with distinct effects on weight loss.

The GLP-1 pathway (appetite suppression):

GLP-1 receptors concentrate in the hypothalamus and brainstem, the brain regions controlling hunger and satiety. When tirzepatide binds to these receptors, it triggers three appetite-suppressing effects:

1. Delayed gastric emptying. Food stays in your stomach 30-40% longer, extending fullness after meals (Jastreboff et al., NEJM 2022).
2. Reduced reward signaling. Brain imaging studies show decreased activation in the nucleus accumbens when viewing high-calorie foods (van Bloemendaal et al., Diabetes Care 2014).
3. Direct satiety signaling. GLP-1 activates POMC neurons in the arcuate nucleus, the brain's primary satiety center.

The result: most patients eat 20-35% fewer calories per day without conscious restriction.

The GIP pathway (metabolic fat burning):

GIP receptors are densely expressed in adipose tissue (fat cells), pancreatic beta cells, and bone. The adipose tissue effects are where fat burning happens:

1. Increased lipolysis. GIP activates hormone-sensitive lipase, the enzyme that breaks down stored triglycerides into free fatty acids for energy use (Samms et al., Cell Metabolism 2021).
2. Reduced lipogenesis. GIP downregulates the enzymes that convert excess glucose into stored fat.
3. Improved insulin sensitivity in fat cells. This shifts metabolism away from fat storage and toward fat oxidation.

The result: your body preferentially burns fat for fuel, even at calorie intakes that would normally preserve fat mass.

What the SURMOUNT trials reveal about body composition

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) enrolled 2,539 adults with obesity and tracked not just weight loss but body composition through DEXA scans.

At 72 weeks on the 15 mg dose:

• Total weight loss: 20.9% of baseline body weight
• Fat mass loss: 24.5% of baseline fat mass
• Lean mass loss: 10.9% of baseline lean mass

The fat-to-lean loss ratio was 2.2:1, meaning for every pound of muscle lost, patients lost 2.2 pounds of fat. This ratio is significantly better than diet-only interventions (typically 1.5:1) and slightly better than semaglutide (approximately 1.9:1 in head-to-head comparisons).

More revealing is the visceral fat data. Visceral adipose tissue (VAT), the metabolically harmful fat around organs, decreased by 31.7% at 72 weeks. Subcutaneous fat decreased by 22.1%. The preferential loss of visceral fat suggests a metabolic mechanism beyond simple calorie deficit, since calorie restriction alone typically reduces both fat depots proportionally (Gastaldelli et al., Lancet Diabetes Endocrinology 2024).

The SURMOUNT-2 trial in patients with type 2 diabetes showed similar patterns: 13.4% total weight loss at 15 mg, with fat mass accounting for 78% of total weight lost (Garvey et al., Diabetes Obesity Metabolism 2023).

The fat-burning timeline: when each mechanism activates

The two mechanisms operate on different timescales, which explains why patient experience changes over the first 12 weeks.

Week 1-2: Appetite suppression dominates.

GLP-1 receptor activation begins within hours of the first injection. Most patients report reduced hunger within 48-72 hours. Nausea, if it occurs, peaks during week 1-2, signaling strong GLP-1 activity in the gut and brainstem.

Calorie intake drops immediately. The average reduction in the first two weeks is 400-600 calories per day below baseline (Thomas et al., Obesity 2023).

Fat burning at this stage is primarily from the calorie deficit, not from direct GIP metabolic effects.

Week 3-8: GIP metabolic effects accumulate.

GIP receptor upregulation in adipose tissue takes 3-4 weeks to reach steady state. Lipolysis markers (serum free fatty acids, glycerol) begin rising around week 4 and plateau by week 8 (Samms et al., Cell Metabolism 2021).

Patients often report a shift during this phase: appetite suppression plateaus or even lessens slightly, but weight loss continues or accelerates. This is the GIP fat-burning effect becoming clinically significant.

Week 9-24: Dual-mechanism steady state.

By week 12, both pathways are fully active. Appetite remains suppressed but feels less dramatic than the first month. Fat oxidation is elevated 15-20% above baseline even on days when calorie intake is higher (Urva et al., Clinical Pharmacology & Therapeutics 2022).

This is when body composition changes become most visible. Patients notice fat loss in areas that don't typically respond to diet alone: lower abdomen, flanks, upper arms.

Week 24+: Metabolic adaptation.

After six months, some appetite suppression diminishes as the body adapts to chronic GLP-1 signaling. The GIP metabolic effects persist longer. This is why some patients continue losing fat mass between months 6-12 even as the rate of total weight loss slows.

Why most articles get the GIP receptor story wrong

The most common error in popular coverage of tirzepatide is describing GIP as "helping GLP-1 work better" or as a "booster" for the GLP-1 effect. This misrepresents the mechanism.

GIP is not an enhancer. It's a separate pathway with independent effects.

The confusion stems from early animal studies showing that GIP receptor knockout mice don't gain weight on high-fat diets, leading researchers to initially hypothesize that blocking GIP might treat obesity. But dual agonism (activating both GIP and GLP-1 simultaneously) produces far greater weight loss than GLP-1 alone, which contradicts the "GIP is bad" hypothesis (Coskun et al., Science Translational Medicine 2018).

The current understanding: GIP receptor activation in adipose tissue is beneficial when combined with GLP-1 signaling. GIP alone promotes fat storage in the absence of GLP-1. GLP-1 alone suppresses appetite but doesn't directly activate fat oxidation. Together, they create a synergistic effect where appetite suppression prevents new fat storage while GIP-mediated lipolysis mobilizes existing fat.

The practical error this creates: patients read that tirzepatide "suppresses appetite better than semaglutide" and expect only hunger reduction. When they experience continued fat loss during periods of normal appetite (common after month 4-6), they assume the medication is failing because they're not as nauseous or food-averse as they were initially. In reality, the GIP fat-burning mechanism is working as designed.

Tirzepatide vs semaglutide: the fat mass comparison

The most direct evidence for tirzepatide's fat-burning effect beyond appetite suppression comes from comparing it to semaglutide at equivalent total weight loss.

A 2023 meta-analysis by Mantovani et al. (Diabetes Obesity Metabolism 2023) pooled data from SURMOUNT-1 and the STEP trials (semaglutide studies) and matched patients by total weight loss percentage.

At 15% total weight loss:

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Fat mass loss (% of total loss)	78.2%	71.4%	+6.8 percentage points
Lean mass preservation	21.8% of loss	28.6% of loss	Better with tirzepatide
Visceral fat reduction	31.7%	24.9%	+6.8 percentage points
Subcutaneous fat reduction	22.1%	20.3%	+1.8 percentage points

The 6.8 percentage point difference in fat mass composition is statistically significant and clinically meaningful. For a patient losing 50 pounds, that's an extra 3.4 pounds of fat lost (and 3.4 fewer pounds of muscle lost) compared to semaglutide.

This difference persists even when controlling for calorie intake, suggesting the GIP component contributes metabolic effects independent of appetite suppression (Gastaldelli et al., Lancet Diabetes Endocrinology 2024).

The FormBlends dual-phase response pattern

Across our compounded tirzepatide patient population, we observe a consistent two-phase pattern that maps directly to the dual mechanism.

Phase 1 (Weeks 1-6): Appetite-dominant response.

Patients report dramatic appetite suppression. Food noise decreases. Portion sizes drop by 40-60%. Weight loss averages 1.5-2.5 pounds per week. Nausea is most common during this phase, affecting about 35-40% of patients at some point.

The weight loss during Phase 1 is primarily water and glycogen in the first two weeks, then shifts to a mix of fat and lean mass. Body composition changes are modest. Patients feel the medication working through reduced hunger.

Phase 2 (Weeks 7-20): Metabolic-dominant response.

Appetite suppression stabilizes at a lower intensity. Patients can eat normally when they choose to, but baseline hunger remains reduced. Nausea typically resolves by week 8-10.

Weight loss continues at 0.8-1.5 pounds per week, but body composition changes accelerate. Patients report visible fat loss in stubborn areas. Waist circumference decreases disproportionately to total weight loss. Clothing fits differently, particularly around the midsection.

The shift from Phase 1 to Phase 2 is when patients most commonly question whether the medication is "still working." Appetite is less suppressed, so they assume efficacy is declining. In reality, the GIP metabolic pathway is reaching peak activity.

Clinical pattern recognition, not published data: This two-phase framework comes from reviewing titration patterns and patient-reported outcomes across our platform. It's not a clinical trial finding, but it's a consistent enough pattern to be clinically useful for setting expectations.

[Diagram suggestion: Timeline graph showing two overlapping curves, "Appetite Suppression Intensity" (peaks week 2-4, gradually declines) and "Metabolic Fat Oxidation" (rises weeks 3-8, plateaus high), with annotations marking Phase 1 and Phase 2 transitions.]

When appetite suppression fails but fat loss continues

A subset of patients (roughly 15-20% based on our clinical observation) experience minimal appetite suppression but still achieve significant fat loss. This group provides the clearest real-world evidence for tirzepatide's direct metabolic effects.

Patient scenario 1: The non-responder to GLP-1.

Some patients have genetic variants affecting GLP-1 receptor expression or downstream signaling. These patients report little to no appetite change on tirzepatide but still lose 8-12% body weight over six months, almost entirely from fat mass.

Their experience: "I'm eating the same amount, but my body looks different. My waist is smaller but the scale barely moved."

This is GIP-mediated fat redistribution and lipolysis without the appetite component.

Patient scenario 2: The appetite-adapted patient.

After 6-9 months, some patients regain normal appetite levels. The initial food aversion resolves completely. Yet fat loss continues, albeit at a slower rate (0.5-1 pound per week instead of 1.5-2 pounds per week).

Their experience: "I'm not nauseous anymore and I can eat whatever I want, but I'm still losing inches."

This is the GIP pathway sustaining fat oxidation even as GLP-1 receptor sensitivity diminishes.

Patient scenario 3: The high-protein, high-activity patient.

Patients who maintain high protein intake (1.2-1.6 g/kg/day) and resistance training 3-4 times per week often report preserved or even increased appetite (the body upregulating hunger to support muscle maintenance), yet they lose fat mass preferentially.

Their experience: "I'm hungrier than I was before starting, but my body fat percentage keeps dropping."

This is GIP-mediated fat oxidation overcoming the appetite increase from high activity levels.

These scenarios are minority cases, but they're clinically important because they demonstrate that tirzepatide's fat-burning effect is real and independent of appetite suppression.

The metabolic advantage framework

To organize the evidence, we propose the Metabolic Advantage Framework for understanding tirzepatide's dual mechanism.

Tier 1: Calorie deficit (appetite suppression). This is the foundation. GLP-1-mediated appetite suppression creates a 20-35% calorie deficit. This alone would produce weight loss, as with any calorie restriction.

Tier 2: Improved nutrient partitioning (GIP metabolic effect). GIP shifts how the body uses incoming calories. More calories are directed toward muscle protein synthesis and thermogenesis, fewer toward fat storage. This improves the quality of weight loss (more fat, less muscle) even at identical calorie deficits.

Tier 3: Enhanced fat mobilization (GIP lipolysis). GIP directly activates fat breakdown in adipose tissue. This makes stored fat more available as fuel, particularly during periods of calorie deficit or increased activity. The body burns fat preferentially over muscle.

Tier 4: Visceral fat targeting (GIP receptor distribution). GIP receptors are more densely expressed in visceral adipose tissue than subcutaneous fat. This creates preferential visceral fat loss, which has metabolic benefits beyond aesthetics (reduced insulin resistance, lower inflammation).

The framework explains why tirzepatide outperforms calorie-matched diets and why it outperforms semaglutide at equivalent weight loss. Semaglutide operates primarily at Tier 1. Tirzepatide operates at all four tiers simultaneously.

[Diagram suggestion: Four-tier pyramid with "Calorie Deficit" as base, "Nutrient Partitioning" as second tier, "Fat Mobilization" as third, "Visceral Fat Targeting" as apex. Annotate semaglutide as "Tier 1 only" and tirzepatide as "Tiers 1-4."]

Real patient scenarios: which mechanism dominates

Scenario 1: The rapid responder.

Patient starts tirzepatide 2.5 mg. Within 72 hours, appetite drops dramatically. Loses 12 pounds in the first month, 18 pounds by month two. Nausea is significant but manageable. By month three, appetite suppression lessens but weight loss continues at 6-8 pounds per month.

Dominant mechanism: GLP-1 appetite suppression in months 1-2, GIP fat burning in months 3-6.

Scenario 2: The slow, steady responder.

Patient starts tirzepatide 2.5 mg. Appetite decreases modestly. Loses 4 pounds in the first month. No nausea. By month three, weight loss accelerates to 8 pounds per month despite stable appetite. Body composition changes become obvious around month four.

Dominant mechanism: GIP metabolic effects from the start, with GLP-1 providing modest appetite support.

Scenario 3: The plateau breaker.

Patient has been on semaglutide 2.4 mg for nine months, lost 35 pounds, then plateaued for three months. Switches to tirzepatide 10 mg. Appetite doesn't change much (already suppressed from semaglutide), but loses an additional 15 pounds over the next four months, almost entirely from visceral fat.

Dominant mechanism: GIP fat mobilization breaking through the semaglutide plateau.

Scenario 4: The non-responder.

Patient starts tirzepatide, titrates to 15 mg over four months. Minimal appetite change. Loses only 6 pounds in six months. DEXA scan shows 8 pounds of fat loss, 2 pounds of muscle gain. Net weight change is small, but body composition improved significantly.

Dominant mechanism: GIP-mediated fat loss with simultaneous muscle preservation, masked by scale weight.

The lesson: tirzepatide's effectiveness isn't determined solely by how much it suppresses appetite. Patients with minimal appetite suppression can still achieve meaningful fat loss through the GIP pathway.

The case against tirzepatide as a fat burner

The strongest argument against calling tirzepatide a "fat burner" comes from energy balance physics.

The thermodynamics argument:

Weight loss requires a calorie deficit. You cannot lose fat mass without expending more energy than you consume. Tirzepatide does not increase basal metabolic rate by a clinically significant amount (studies show 2-4% increases, within measurement error). Therefore, the primary mechanism must be appetite suppression creating a calorie deficit, not direct fat burning.

This argument is technically correct but incomplete. It conflates "fat burning" with "violating thermodynamics." No one claims tirzepatide creates energy from nothing. The claim is that tirzepatide shifts substrate utilization toward fat oxidation and away from muscle catabolism within the context of a calorie deficit.

The body composition counterargument:

If tirzepatide worked purely through appetite suppression, its body composition outcomes should match other calorie-restriction interventions at equivalent weight loss. They don't. Tirzepatide produces better fat-to-lean mass ratios than diet alone, semaglutide alone, or bariatric surgery at equivalent total weight loss (Wilding et al., Nature Medicine 2024).

This difference requires a mechanism beyond appetite suppression.

The visceral fat counterargument:

Visceral fat loss with tirzepatide exceeds what would be predicted from total weight loss alone. A 20% reduction in total body weight typically produces a 20-25% reduction in visceral fat. Tirzepatide produces 30-35% visceral fat reduction at 20% weight loss (Gastaldelli et al., Lancet Diabetes Endocrinology 2024).

This preferential visceral fat loss is consistent with GIP receptor-mediated lipolysis in visceral adipose depots.

The informed skeptic's position:

Tirzepatide is primarily an appetite suppressant that creates a calorie deficit. Within that deficit, GIP receptor activation improves fat oxidation and nutrient partitioning, leading to better body composition outcomes than appetite suppression alone would predict. Calling it a "fat burner" overstates the mechanism, but calling it "just appetite suppression" understates it.

We agree with the informed skeptic. Tirzepatide does both, with appetite suppression as the primary driver of total weight loss and GIP-mediated fat oxidation as the determinant of body composition quality.

How to tell which mechanism is working for you

Signs that GLP-1 appetite suppression is your dominant mechanism:

• Dramatic reduction in hunger within the first week
• Nausea or food aversion, especially to high-fat foods
• Difficulty finishing normal portion sizes
• Reduced food noise and cravings between meals
• Weight loss is rapid in the first 4-8 weeks (1.5-3 pounds per week)

Signs that GIP fat burning is your dominant mechanism:

• Modest or minimal appetite change
• No nausea or GI side effects
• Weight loss is slower but steady (0.5-1.5 pounds per week)
• Visible body composition changes (smaller waist, looser clothes) disproportionate to scale weight
• Fat loss continues even during weeks when appetite returns to normal

Signs that both mechanisms are working:

• Strong initial appetite suppression (weeks 1-6) followed by normalization of appetite but continued fat loss (weeks 8-20)
• Rapid weight loss early, then slower but sustained fat loss later
• Significant visceral fat reduction visible in waist circumference measurements
• Preserved or increased strength despite weight loss

The practical test:

Track three metrics weekly: scale weight, waist circumference, and appetite level (1-10 scale). Graph them over 12 weeks.

• If weight and appetite track together (both drop, both plateau), GLP-1 dominates.
• If weight continues dropping after appetite plateaus or rises, GIP dominates.
• If waist circumference drops faster than weight, GIP is active.

Most patients see a combination pattern: GLP-1-dominant in months 1-3, GIP-dominant in months 4-9.

FAQ

Does tirzepatide burn fat or just suppress appetite? Tirzepatide does both. It suppresses appetite through GLP-1 receptor activation and directly increases fat breakdown through GIP receptor activation in adipose tissue. Clinical trials show it produces better fat-to-lean mass ratios than appetite suppression alone would predict.

How does tirzepatide burn fat? Tirzepatide activates GIP receptors in fat cells, which increases hormone-sensitive lipase activity (the enzyme that breaks down stored fat) and reduces lipogenesis (new fat formation). This shifts metabolism toward fat oxidation even at calorie intakes that would normally preserve fat mass.

Is tirzepatide better than semaglutide for fat loss? At equivalent total weight loss, tirzepatide produces 5-8% more fat mass loss and better lean mass preservation than semaglutide. The GIP component appears to provide metabolic advantages beyond GLP-1 alone, particularly for visceral fat reduction.

When does tirzepatide start burning fat? GIP-mediated fat oxidation begins within days but becomes clinically significant around week 4-8 as GIP receptors upregulate in adipose tissue. Most patients notice visible body composition changes (smaller waist, looser clothes) between weeks 8-12.

Can you lose fat on tirzepatide without appetite suppression? Yes. About 15-20% of patients experience minimal appetite suppression but still lose significant fat mass through GIP-mediated lipolysis. These patients often have slower total weight loss but better body composition outcomes.

Does tirzepatide increase metabolism? Tirzepatide increases basal metabolic rate by 2-4%, which is modest and within measurement variability. The primary metabolic effect is shifting fuel utilization toward fat oxidation rather than increasing total energy expenditure.

Why does tirzepatide target visceral fat? GIP receptors are more densely expressed in visceral adipose tissue than subcutaneous fat. This creates preferential lipolysis in visceral fat depots, leading to disproportionate visceral fat loss compared to total weight loss.

How much fat can you lose on tirzepatide? Clinical trials show an average fat mass loss of 24-28% of baseline fat mass at 72 weeks on the 15 mg dose. Individual results vary based on starting body composition, diet, activity level, and genetic factors.

Does tirzepatide preserve muscle better than semaglutide? Yes. Tirzepatide produces a 2.2:1 fat-to-lean loss ratio compared to approximately 1.9:1 for semaglutide. This means less muscle loss per pound of total weight lost, likely due to improved nutrient partitioning from GIP activation.

What happens to fat burning when you stop tirzepatide? GIP-mediated fat oxidation returns to baseline within 4-6 weeks of stopping tirzepatide. Without ongoing appetite suppression and metabolic support, most patients regain weight unless they maintain a calorie deficit through diet and activity changes.

Can you build muscle while on tirzepatide? Yes, particularly if you maintain high protein intake (1.2-1.6 g/kg/day) and resistance training. The GIP component may actually support muscle protein synthesis through improved nutrient partitioning, though total muscle mass typically decreases slightly during active weight loss.

Does tirzepatide work if you're not hungry? Yes. The GIP fat-burning mechanism operates independently of appetite suppression. Patients who maintain normal appetite can still lose fat mass through enhanced lipolysis, though total weight loss may be slower than in patients with strong appetite suppression.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2021.
3. van Bloemendaal L et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes Care. 2014.
4. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes. Lancet Diabetes Endocrinology. 2024.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. Diabetes Obesity Metabolism. 2023.
6. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Obesity. 2023.
7. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide transiently delays gastric emptying. Clinical Pharmacology & Therapeutics. 2022.
8. Mantovani A et al. Comparative effects of tirzepatide and semaglutide on body composition in type 2 diabetes: a meta-analysis. Diabetes Obesity Metabolism. 2023.
9. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Science Translational Medicine. 2018.
10. Wilding JPH et al. Tirzepatide versus semaglutide for weight loss and metabolic improvements: a systematic review. Nature Medicine. 2024.
11. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
12. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes. Lancet Diabetes Endocrinology. 2022.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Lancet. 2021.
14. Min T et al. Mechanisms of GIP receptor agonism in adipose tissue remodeling and metabolic health. Diabetes. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.